"Fluvoxamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.
| Descriptor ID |
D016666
|
| MeSH Number(s) |
D02.092.570.665.250
|
| Concept/Terms |
Luvox- Luvox
- Floxyfral
- Fevarin
- Dumirox
- Faverin
|
Below are MeSH descriptors whose meaning is more general than "Fluvoxamine".
Below are MeSH descriptors whose meaning is more specific than "Fluvoxamine".
This graph shows the total number of publications written about "Fluvoxamine" by people in this website by year, and whether "Fluvoxamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 2 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fluvoxamine" by people in Profiles.
-
Old drug fluvoxamine, new hope for COVID-19. Eur Arch Psychiatry Clin Neurosci. 2022 Feb; 272(1):161-163.
-
Remote Research and Clinical Trial Integrity During and After the Coronavirus Pandemic. JAMA. 2021 05 18; 325(19):1935-1936.
-
Are Persons Treated with Antidepressants and/or Antipsychotics Possibly Better Protected against Severe COVID 19? Pharmacopsychiatry. 2021 05; 54(3):142-143.
-
Homozygosity for rs17775810 Minor Allele Associated With Reduced Mortality of COVID-19 in the UK Biobank Cohort. In Vivo. 2021 Mar-Apr; 35(2):965-968.
-
Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19. Int J Mol Sci. 2021 Feb 11; 22(4).
-
Fluvoxamine, melatonin and COVID-19. Psychopharmacology (Berl). 2021 02; 238(2):611.
-
COVID-19 Clinical Trials: A Voice From the Front Lines. Narrat Inq Bioeth. 2021; 11(1):16-19.
-
[COVID-19 and stress-related disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2021; 121(5. Vyp. 2):122-128.
-
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020 12 08; 324(22):2292-2300.
-
COVID-19 Infection-Preventing Clinical Deterioration. JAMA. 2020 12 08; 324(22):2300.